GlassScriptPhysician profile
Marissa M King
NPI 1518522648
$3,842.15
in general payments reported to CMS, 2019-2025
25 companies · $807 in 2025
The $807 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $212 · 2023: $913 · 2024: $1,633 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,517.18 | 2023-2025 | Impella |
| Pfizer INC. | $404.83 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $401.02 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.64 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $210.36 | 2021-2025 | |
| Boston Scientific Corporation | $204.61 | 2021-2025 | Watchman Access System, Watchman Flx |
| Abbott Laboratories | $103.46 | 2025 | Cardiomems |
| Medtronic, INC. | $93.25 | 2022-2025 | Apollotm, Cg Future |
| Kestra Medical Technology Services, INC. | $80.82 | 2024-2025 | Assure Wcd |
| Amgen INC. | $77.18 | 2024-2025 | Repatha, Repatha |
| Cvrx, INC. | $70.21 | 2021-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $58.19 | 2021-2025 | Wainua |
| Regeneron Healthcare Solutions, INC. | $52.69 | 2023-2025 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $51.42 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $41.93 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $39.87 | 2021-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $32.84 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $27.38 | 2021 | |
| Endotronix, INC. | $26.74 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| E.R. Squibb & Sons, L.L.C. | $24.89 | 2025 | Camzyos |
| Esperion Therapeutics, INC. | $19.68 | 2025 | Nexletol |
| Atricure, INC. | $18.22 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.72 | 2025 | |
| Scpharmaceuticals INC. | $15.53 | 2023 | |
| Elutia, INC. | $10.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.